Department of Safety Sciences & Imaging, 1450Novo Nordisk A/S, Måløv, Denmark.
Department of DMPK (Drug Metabolism and Pharmacokinetics) and Non-clinical Project Management, 1450Novo Nordisk A/S, Måløv, Denmark.
Int J Toxicol. 2022 Dec;41(6):455-475. doi: 10.1177/10915818221121054. Epub 2022 Aug 27.
N9-GP/Rebinyn/Refixia is an approved PEGylated (polyethylene glycol-conjugated) recombinant human factor IX intended for prophylactic and/or on-demand treatment in adults and children with haemophilia B. A juvenile neurotoxicity study was conducted in male rats to evaluate effects on neurodevelopment, sexual maturation, and fertility following repeat-dosing of N9-GP. Male rats were dosed twice weekly from Day 21 of age with N9-GP or vehicle for 10 weeks, followed by a dosing-free recovery period for 13 weeks and terminated throughout the dosing and recovery periods. Overall, dosing N9-GP to juvenile rats did not result in any functional or pathological effects, as measured by neurobehavioural/neurocognitive tests, including motor activity, sensory function, learning and memory as well as growth, sexual maturation, and fertility. This was further supported by the extensive histopathologic evaluation of brain tissue. Exposure and distribution of polyethylene glycol was investigated in plasma, choroid plexus, cerebrospinal fluid, and brain sections. PEG did not cross the blood brain barrier and PEG exposure did not result in any effects on neurodevelopment. In conclusion, dosing of N9-GP to juvenile rats did not identify any effects on growth, sexual maturation and fertility, clinical and histological pathology, or neurodevelopment related to PEG exposure and supports the prophylactic use of N9-GP in children.
N9-GP/瑞斌宁/瑞福是一种已获批的聚乙二醇(PEG)缀合重组人凝血因子 IX,拟用于乙型血友病成人和儿童的预防和(或)按需治疗。一项在雄性大鼠中开展的幼年动物神经毒性研究,旨在评估重复给予 N9-GP 对神经发育、性成熟和生育力的影响。雄性大鼠从出生后第 21 天开始每周两次接受 N9-GP 或赋形剂治疗,共 10 周,随后进行为期 13 周的无给药恢复期,并在整个给药和恢复期结束时处死。总体而言,幼年大鼠重复给予 N9-GP 并未导致任何功能或病理影响,这可通过神经行为/神经认知测试(包括运动活动、感觉功能、学习和记忆)以及生长、性成熟和生育力来衡量。脑组织的广泛组织病理学评估进一步支持了这一结果。在血浆、脉络丛、脑脊液和脑组织切片中研究了聚乙二醇的暴露和分布。PEG 未穿过血脑屏障,且 PEG 暴露并未对神经发育产生任何影响。因此,幼年大鼠重复给予 N9-GP 不会影响生长、性成熟和生育力、临床和组织病理学,也不会影响与 PEG 暴露相关的神经发育。结论为,N9-GP 可用于儿童预防治疗,不会导致与 PEG 暴露相关的生长、性成熟和生育力、临床和组织病理学或神经发育方面的影响。